Activity of 3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam-p-bis(2-chloroethyl)aminophenoxyacetate (NSC 294859) on experimental animal tumor and leukemia systems.
3 beta-hydroxy-13 alpha-amino-13,17-seco-5 alpha-androstan-17-oic-13,17-lactam-p-bis(2-chloroethyl)amino-phenoxyacetate, a modified steroidal alkylating agent, is active in the treatment of colon 26 tumor, B16 melanoma and P388 leukemia.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy* / Q000473:pathology; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*; D013997:Time Factors
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; C038583:NSC 294859